No Data
No Data
BioXcel Therapeutics Shares Rise After Preliminary Q2 Revenue Exceeds Estimates
Express News | BioXcel Therapeutics Announced Preliminary Sales Of Igalmi (Dexmedetomidine) Sublingual Film For Q2 Of Approximately $1.1M, Up Approximately 90% Quarter Over Quarter And Approximately 141% Year-over-year
Express News | BioXcel Therapeutics Inc Sees Unaudited Revenue of About $1.1 Mln for Three Months Ended June 30
Express News | BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues From Sales of Igalmi™ (Dexmedetomidine) Sublingual Film
Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Maintains $7 Price Target
CCORF Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Maintains Target Price $7
No Data